| Safety of encainide for the treatment of ventricular arrhythmias. | |
| | |
MedLine Citation:
|
PMID: 3092626 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A data base of 1,245 patients treated for ventricular arrhythmias, most of whom had serious cardiac disease, was reviewed. Only 2.9% of these patients had benign ventricular arrhythmias without structural heart disease. The overall incidence of proarrhythmia in this population was 9.2% (115/1,245), but was as frequent as 16% in patients with a history of cardiomyopathy. The proarrhythmic form was new sustained ventricular tachycardia in 22 patients (1.8%). Only 2 of 71 patients (2.8%) with primary arrhythmia had a proarrhythmic event. The incidence has decreased markedly over the past years as reduced doses and gradual titration have been used. There were 137 deaths in the data base of which 82 were sudden, all in patients with advanced (79) or moderately severe (3) cardiac disease. High initial doses, prior myocardial infarction and congestive heart failure (CHF) were positively associated with sudden cardiac death. There were no deaths among the 71 patients with benign arrhythmias. Death rates were related to the severity of the arrhythmia being treated. Comparisons with published survival curves indicated modest improvement; in no case was survival decreased. Invasive and noninvasive measures of left ventricular function indicated no adverse hemodynamic effects. There was only 1 case of new and 3 cases of worsened CHF probably related to encainide. Only 5 patients discontinued for CHF or related signs and symptoms. The most frequent drug-related noncardiac adverse reactions were dizziness (26%), abnormal or blurred vision (19%), QRS interval prolongation (5%), taste perversion (4%) and tremor (3%). In conclusion, the use of reduced doses and gradual titration of encainide has markedly decreased the incidence of proarrhythmia.(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
L F Soyka |
Related Documents
:
|
21917186 - Myocardial area at risk and salvage measured by t2-weighted cardiovascular magnetic res... 6821616 - Effect of intravenous adrenaline on electrocardiogram, blood pressure, and serum potass... 434996 - Control of refractory cardiac arrhythmias with amiodarone. 317206 - Arrhythmias in organophosphate poisonings. 21968546 - Contrast material injection protocol with the flow rate adjusted to the heart rate for ... 8987966 - Extracellular matrix and cardiovascular diseases. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The American journal of cardiology Volume: 58 ISSN: 0002-9149 ISO Abbreviation: Am. J. Cardiol. Publication Date: 1986 Aug |
Date Detail:
|
Created Date: 1986-10-06 Completed Date: 1986-10-06 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0207277 Medline TA: Am J Cardiol Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 96C-103C Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Anilides / adverse effects, therapeutic use* Arrhythmias, Cardiac / complications, drug therapy*, mortality Electrocardiography Encainide Heart Failure / complications Heart Ventricles Hemodynamics / drug effects Humans Middle Aged Retrospective Studies |
| Chemical | |
Reg. No./Substance:
|
0/Anilides; 66778-36-7/Encainide |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Safety and efficacy of encainide for malignant ventricular arrhythmias.
Next Document: Alterations in regional myocardial blood flow after nitroprusside and nitroglycerin in patients with...